Insys Therapeutics (INSY) Downgraded by ValuEngine

ValuEngine downgraded shares of Insys Therapeutics (NASDAQ:INSY) from a buy rating to a hold rating in a report released on Thursday.

Separately, Zacks Investment Research raised Insys Therapeutics from a sell rating to a hold rating in a research report on Thursday, October 11th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $7.67.

Insys Therapeutics stock opened at $4.91 on Thursday. Insys Therapeutics has a one year low of $4.80 and a one year high of $14.00.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings data on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). Insys Therapeutics had a negative net margin of 128.88% and a negative return on equity of 266.60%. The business had revenue of $18.30 million for the quarter, compared to analysts’ expectations of $24.05 million. During the same period last year, the business earned ($2.30) earnings per share. The company’s quarterly revenue was down 40.4% on a year-over-year basis. Analysts anticipate that Insys Therapeutics will post -1.32 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Insys Therapeutics in the third quarter worth about $113,000. Tower Research Capital LLC TRC purchased a new position in Insys Therapeutics in the second quarter worth about $131,000. Creative Planning purchased a new position in Insys Therapeutics in the third quarter worth about $153,000. MetLife Investment Advisors LLC purchased a new position in Insys Therapeutics in the third quarter worth about $223,000. Finally, BNP Paribas Arbitrage SA boosted its position in Insys Therapeutics by 47.4% in the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after purchasing an additional 10,001 shares during the last quarter. 17.22% of the stock is currently owned by institutional investors.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Read More: What is dollar cost averaging (DCA)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply